Seribantumab
Seribantumab
Seribantumab (pronunciation: se-ri-ban-tu-mab) is a monoclonal antibody designed for the treatment of cancer. It is developed by Merrimack Pharmaceuticals and is currently in the clinical trial phase.
Etymology
The name "Seribantumab" is derived from the International Nonproprietary Names (INN), where "seri-" refers to the genus of the source organism, "-ban-" refers to the target, and "-tumab" is a suffix used in the names of monoclonal antibodies.
Mechanism of Action
Seribantumab works by binding to the HER3 receptor, a protein that is overexpressed in certain types of cancer. By blocking this receptor, Seribantumab can inhibit the growth and proliferation of cancer cells.
Clinical Trials
Seribantumab has been tested in several clinical trials for various types of cancer, including breast cancer, lung cancer, and pancreatic cancer. The results of these trials have shown promise, but further research is needed to determine the drug's efficacy and safety profile.
Related Terms
- Monoclonal antibody
- HER3 receptor
- Merrimack Pharmaceuticals
- Clinical trial
- Breast cancer
- Lung cancer
- Pancreatic cancer
External links
- Medical encyclopedia article on Seribantumab
- Wikipedia's article - Seribantumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski